Merck says Ebola vaccine to be available at lowest access price for poor nations

Merck&Co said on Friday it expects to make licensed doses of its recently approved Ebola vaccine available in the third quarter of 2020 and price the single-dose injection at the lowest possible access price for poor and middle-income countries.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Authors: Batra S, Ochani RK, Diwan MN, Yasmin F, Qureshi SS, Bhimani S, Shaikh S, Tariq MA, Ahmed Ashraf M, Farooqi HA, Dodani SK Abstract Ebola Virus Disease (EVD), also known as Ebola Hemorrhagic Fever (EHF), initially emerged over 40 years ago in the Democratic Republic of Congo. Endemic to Africa, outbreaks have been recorded in six African countries since its detection in 1976. Fruit bats are believed to be the natural hosts of Ebola viruses (EBoV), with humans and other mammals serving as accidental hosts. Transmission of EBoV has been reported in various ways, including human to human transmission through cl...
Source: Infezioni in Medicina - Category: Infectious Diseases Tags: Infez Med Source Type: research
From 2018-2019, the Bill and Melinda Gates Foundation gave more money to the World Health Organization than any entity except the U.S. government. With President Donald Trump cutting ties to the international health agency in the midst of the COVID-19 pandemic, the Gates Foundation’s work has come into sharper relief than ever. Co-chair Bill Gates announced at the Global Vaccine Summit on June 4 that it will give $1.6 billion over five years to the Vaccine Alliance (GAVI), to help ensure that people around the world have access to vaccines, regardless of income. The Gates Foundation in 1999 pledged $750 million to he...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
[allAfrica] Washington, DC -Almost 50 responders from the World Health Organization (WHO) and its partners arrived today in Mbandaka in the Democratic Republic of Congo (DRC), along with 3600 doses of Ebola vaccine and 2000 cartridges for lab testing, WHO Director-General Dr. Tedros Adhanom Ghebreyesus told media in an online briefing.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
By Daud Khan and Leila Yasmine KhanAMSTERDAM/ROME, Jun 1 2020 (IPS) As the COVID-19 virus spread rapidly around the globe, so did various theories about what caused the pandemic. According to the standard scientific theory, the virus probably originated in bats and then crossed over to humans, probably via another intermediate host. It then spread rapidly across the globe, piggybacking on the international travel network. While the mainstream scientific theory sufficed for some, a large number of people saw the pandemic as the work of cold-hearted military or industrial strategists. An equally large number of people saw it...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health Source Type: news
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
A panel of the European health regulator on Friday recommended approving Johnson&Johnson's two-dose experimental vaccine for Ebola in the European Union.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
This article is protected by copyright. All rights reserved. PMID: 32463974 [PubMed - as supplied by publisher]
Source: Biotechnology Journal - Category: Biotechnology Authors: Tags: Biotechnol J Source Type: research
The COVID-19 pandemic has had significant global consequences, with healthcare systems stretched to their limits, a growing death toll, and economic devastation as economies came grinding to a halt. The pandemic and its aftereffects will be with u...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Public Health Source Type: blogs
The novel coronavirus strain, severe acute respiratory syndrome coronavirus-2, the causative agent of COVID-19 emerged in Wuhan, China, in December 2019 and is skyrocketing throughout the globe and become a global public health emergency. Despite promising preventive measures being taken, there is no vaccine or drug therapy officially approved to prevent or treat the infection. Everybody is waiting the findings of ongoing clinical trials in various chemical and biological products. This review is specifically aimed to summarize the available evidence and ongoing clinical trials of remdesivir as a potential therapeutic opti...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
On May 1, the U.S Food and Drug Administration issued an emergency-use authorization of remdesivir, an experimental anti-viral drug. With this clearance, doctors in the U.S. are now allowed to use the drug to treat patients with severe cases of COVID-19. Remdesivir isn’t new. It was initially developed to treat Ebola and was also tested in the lab against SARS and MERS—two other coronaviruses that infect humans much like the virus that causes COVID-19. It never made it to the approval stage for those uses, but over the last four months, scientists desperate for options to help mitigate the coronavirus pandemic ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Ebola | Ebola Vaccine | Health | Merck | Vaccines